GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » EV-to-EBITDA

Lirum Therapeutics (Lirum Therapeutics) EV-to-EBITDA : 0.00 (As of Jun. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lirum Therapeutics's enterprise value is $0.00 Mil. Lirum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.30 Mil. Therefore, Lirum Therapeutics's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Lirum Therapeutics's EV-to-EBITDA or its related term are showing as below:

LRTX's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.01
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-11), Lirum Therapeutics's stock price is $0.00. Lirum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Lirum Therapeutics's PE Ratio (TTM) for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Lirum Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Lirum Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics EV-to-EBITDA Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
EV-to-EBITDA - - - - -

Competitive Comparison of Lirum Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Lirum Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lirum Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's EV-to-EBITDA falls into.



Lirum Therapeutics EV-to-EBITDA Calculation

Lirum Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-0.298
=0.00

Lirum Therapeutics's current Enterprise Value is $0.00 Mil.
Lirum Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lirum Therapeutics  (NAS:LRTX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Lirum Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00/0.000
=N/A

Lirum Therapeutics's share price for today is $0.00.
Lirum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Lirum Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines